New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 10, 2013
18:55 EDTLLY, SNY, NVONovo Nordisk receives FDA 'Complete Response Letter" for Tresiba and Ryzodeg
Novo Nordisk announced that on 8 February it received a Complete Response Letter from the US Food and Drug Administration, FDA, regarding the New Drug Applications for Tresiba (insulin degludec) and Ryzodeg (insulin degludec/insulin aspart). A complete Response Letter is issued by the FDA, when the agency determines that an application cannot be approved in its current form. Reference Link
News For NVO;SNY;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
February 9, 2016
08:08 EDTSNYSanofi sees FY16 business EPS to be broadly stable at CER
Subscribe for More Information
05:28 EDTSNYSanofi reports Q4 business EPS down 5.8% to EUR 1.31
Subscribe for More Information
February 8, 2016
10:00 EDTNVOOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: A-Mark Precious Metals (AMRK) downgraded to Neutral from Buy at B. Riley... Antero Midstream (AM) downgraded to Neutral from Outperform at Baird... AstraZeneca (AZN) downgraded to Hold from Buy at HSBC... Baker Hughes (BHI) downgraded to Equal Weight at Morgan Stanley... Brixmor (BRX) downgraded to Neutral from Outperform at Boenning & Scattergood... CBOE Holdings (CBOE) downgraded to Underperform from Outperform at CLSA... Cisco (CSCO) downgraded to Buy from Conviction Buy at Goldman... Citi Trends (CTRN) downgraded to Neutral from Buy at MKM Partners... Commerzbank (CRZBY) downgraded to Underperform from Market Perform at Keefe Bruyette... DexCom (DXCM) downgraded to Neutral from Outperform at Baird... EnLink Midstream (ENLC) downgraded to Underperform from Outperform at Baird... Energy Transfer Equity (ETE) downgraded to Neutral from Outperform at Baird... Energy Transfer Partners (ETP) downgraded to Neutral from Outperform at Baird... Eversource (ES) downgraded to Equal Weight from Overweight at Barclays... Genesis Healthcare (GEN) downgraded to Sell from Neutral at UBS... Givaudan (GVDNY) downgraded to Neutral from Buy at Goldman... HSBC (HSBC) downgraded to Underweight from Equal Weight at Morgan Stanley... Nomura (NMR) downgraded to Hold from Buy at Deutsche Bank... Novo Nordisk (NVO) downgraded to Sell from Neutral at UBS... ONEOK Partners (OKS) downgraded to Underperform from Neutral at Baird... ONEOK (OKE) downgraded to Neutral from Outperform at Baird... PPL Corp. (PPL) downgraded to Hold from Buy at Evercore ISI... Plains All American (PAA) downgraded to Underperform from Outperform at Baird... Plains GP Holdings (PAGP) downgraded to Underperform from Neutral at Baird... Quanta Services (PWR) downgraded to Neutral from Buy at UBS... Ralph Lauren (RL) downgraded to Neutral from Overweight at Atlantic Equities... Sparton (SPA) downgraded to Market Perform from Outperform at Barrington... Tableau (DATA) downgraded to Equal Weight at Morgan Stanley... Tallgrass Energy GP (TEGP) downgraded to Neutral from Outperform at Baird... WisdomTree (WETF) downgraded to Underperform from Market Perform at Keefe Bruyette.
06:28 EDTSNY, LLYPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
05:36 EDTNVONovo Nordisk downgraded to Sell from Neutral at UBS
Subscribe for More Information
February 4, 2016
11:13 EDTNVONovo Nordisk management to meet with Jefferies
Meeting to be held in Geneva on February 11 hosted by Jefferies.
February 2, 2016
11:09 EDTSNYSanofi plans to cut 600 jobs in France over three years, Bloomberg reports
Subscribe for More Information
08:36 EDTNVOPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
07:24 EDTSNYSanofi, Merck mulling exiting vaccine JV, Bloomberg reports
Subscribe for More Information
05:19 EDTSNYSanofi Pasteur launches R&D project targeting prevention of Zika virus infection
Subscribe for More Information
February 1, 2016
06:18 EDTLLYTransition Therapeutics announces results from Phase 2 clinical study of TT401
Subscribe for More Information
06:11 EDTLLYTransition Therapeutics reports results from Phase 2 clinical study of TT401
Subscribe for More Information
January 29, 2016
13:38 EDTSNYAmgen wins right to allege willful infringement in Praluent suit, Markman says
Subscribe for More Information
05:20 EDTLLYEli Lilly, Adocia initiate Phase 1b study of BioChaperone Lispro U100
Adocia and Eli Lilly announced the initiation of a Phase 1b clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia's proprietary technology, BioChaperone, which is designed to enable the acceleration of insulin absorption. The study, under the Adocia-Lilly partnership, aims to compare the pharmacokinetic and pharmacodynamic profiles of BioChaperone Lispro to that of Humalog in 15 healthy Japanese subjects placed under euglycemic clamp.
January 28, 2016
09:55 EDTLLYEli Lilly nears test of key support at $80 area
Subscribe for More Information
06:29 EDTLLYEli Lilly backs FY16 adjusted EPS view of $3.45-$3.55, consensus $3.54
Backs FY16 revenue guidance of $20.2B-$20.7B, consensus $20.83B.
06:27 EDTLLYEli Lilly reports Q4 EPS 78c, consensus 78c
Reports Q4 revenue $5.38B, consensus $5.32B.
January 27, 2016
14:44 EDTLLYEli Lilly volatility elevated into Q4 and outlook
Eli Lilly January weekly call option implied volatility is at 54, February is at 29; compared to its 52-week range of 15 to 41, suggesting large near term price movement into the expected release of Q4 results on January 28.
14:34 EDTLLYNotable companies reporting before tomorrow's open
Subscribe for More Information
09:02 EDTLLYEli Lilly and Roche to collaborate on Alzheimer's diagnostic tool
Subscribe for More Information
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use